Офтальмохирургия. 2016; : 79-83
ОСОБЕННОСТИ КЛИНИЧЕСКОГО ТЕЧЕНИЯ И КОМПЛЕКСНОЙ ТЕРАПИИ ВЕСЕННЕГО КАТАРА (КЛИНИЧЕСКИЙ СЛУЧАЙ)
https://doi.org/undefinedАннотация
Цель. Оценить возможности медикаментозного ведения поражения конъюнктивы без механической деструкции фолликулов.
Материал и методы. Произведен анализ литературы, показан алгоритм современной диагностики и терапии весеннего катара.
Результаты. На фоне применения противоаллергического лечения, глюкокортикостероидов в низкой концентрации, 0,05% Циклоспорина А в сочетании с слезозаместительной терапией удалось получить регресс симптомов заболевания.
Заключение. На основании современных представлений об иммуномодулирующей местной терапии сделан выбор в пользу терапевтического ведения тяжелой патологии конъюнктивы.
Список литературы
1. Лорткипанидзе М.Н. Особенности клиники и современная терапия атопического кератоконъюнктивита: Дис. … канд. мед. наук. – М., 2007. – 119 с.
2. Майчук Ю.Ф. Аллергические болезни глазной поверхности // Синдром «красного глаза»: Практ. рук. для врачей-офтальмологов / Под. ред. Д.Ю. Майчука. – М., 2010. – 108 с.
3. Bremond-Gignac D., Donadieu J., Leonardi A. et al. Prevalence of VKC: a rare disease? // Br. J. Ophthalmol. – 2008. – Vol. 92, № 8. – P. 1097-1102.
4. Coban-Carataș M., Ozkale Y., AltanYaycıoğlu R. et al. Efficacy of topical 0.05% cyclosporine treatment in children with severe vernal keratoconjunctivitis // Turk. J. Pediatr. – 2014. – Vol. 56. – P. 410-417.
5. Cook E.B., Stahl J.L., Barney N.P. et al. Olopatadine inhibits anti-immunoglobulin E-stimulated conjunctival mast cell upregulation of ICAM-1 expression on conjunctival epithelial cells // Ann. Allergy Asthma Immunol. – 2001. – Vol. 87. – P. 424-429.
6. Freeman N., MBChB FC Ophth. Vernal Keratoconjunctivitis // Curr. Allergy Clinic. Immunol. – 2006. – Vol. 19, № 2. – P. 43-52.
7. Leonardi A., Busca F., Motterle L. et al. Case series of 406 vernal keratoconjunctivitis patients: a demographic and epidemiological study // Acta Ophthalmol. Scand. – 2006. – Vol. 84. – P. 406-410.
8. Leonardi A. Management of vernal keratoconjunctivits // Ophthalmol. Ther. – 2013. – Vol. 2, № 2. – Р. 73-88.
9. Jina M., Amar L. Combination of azelastine and mometasone for nasal administration. United States Patent 8937057.
10. Kumar G.S., Kumar A., Verma A. et al. Treatment of VKC comparison between topical Cyclosporine 0.05% and Fluorometholone 0.1% in terms of efficacy and safety // Ind. J. Clin. Exp. Ophthalmol. – 2015. – Vol. 1, № 1. – Р. 22-28.
11. Pucci N., Novembre E., Cianferoni A. et al. Efficacy and safety of CSA eyedrops in vernal keratoconjunctivitis // Ann. Allergy Asthma Immunol. – 2002. – Vol. 89, № 3. – P. 298-303.
12. Yanni J.M., Gamache D.A., Spellman J.M. et al. Comparative effects of topical ocular anti-allergy drugs on human conjunctival mast cells // Ann. Allergy Asthma Immunol. – 1997. – Vol. 79. – P. 541-545.
Fyodorov Journal of Ophthalmic Surgery. 2016; : 79-83
FEATURES OF CLINICAL COURSE AND COMBINED THERAPY OF VERNAL KERATOCONJUNCTIVITIS (A CASE REPORT)
https://doi.org/undefinedAbstract
Purpose. To estimate a possibility of therapeutic management of conjunctiva lesion without mechanical destruc tion of follicles.
Material and methods. The article performs an analysis of literature showing an algorithm of the up-to-dated diagnosis and treatment of patient with vernal keratoconjunctivitis.
Results. Treatment with antiallergic drugs, glyco-corticosteroids in a low concentration, 0.05% Cyclosporine A in combination with the artificial tears therapy enabled to obtain a regression of symptoms.
Conclusion. On the basis of modern concepts of local immunomodulatory therapy the choice was made in favor of the therapeutic management of severe pathology of the conjunctiva.
References
1. Lortkipanidze M.N. Osobennosti kliniki i sovremennaya terapiya atopicheskogo keratokon\"yunktivita: Dis. … kand. med. nauk. – M., 2007. – 119 s.
2. Maichuk Yu.F. Allergicheskie bolezni glaznoi poverkhnosti // Sindrom «krasnogo glaza»: Prakt. ruk. dlya vrachei-oftal'mologov / Pod. red. D.Yu. Maichuka. – M., 2010. – 108 s.
3. Bremond-Gignac D., Donadieu J., Leonardi A. et al. Prevalence of VKC: a rare disease? // Br. J. Ophthalmol. – 2008. – Vol. 92, № 8. – P. 1097-1102.
4. Coban-Carataș M., Ozkale Y., AltanYaycıoğlu R. et al. Efficacy of topical 0.05% cyclosporine treatment in children with severe vernal keratoconjunctivitis // Turk. J. Pediatr. – 2014. – Vol. 56. – P. 410-417.
5. Cook E.B., Stahl J.L., Barney N.P. et al. Olopatadine inhibits anti-immunoglobulin E-stimulated conjunctival mast cell upregulation of ICAM-1 expression on conjunctival epithelial cells // Ann. Allergy Asthma Immunol. – 2001. – Vol. 87. – P. 424-429.
6. Freeman N., MBChB FC Ophth. Vernal Keratoconjunctivitis // Curr. Allergy Clinic. Immunol. – 2006. – Vol. 19, № 2. – P. 43-52.
7. Leonardi A., Busca F., Motterle L. et al. Case series of 406 vernal keratoconjunctivitis patients: a demographic and epidemiological study // Acta Ophthalmol. Scand. – 2006. – Vol. 84. – P. 406-410.
8. Leonardi A. Management of vernal keratoconjunctivits // Ophthalmol. Ther. – 2013. – Vol. 2, № 2. – R. 73-88.
9. Jina M., Amar L. Combination of azelastine and mometasone for nasal administration. United States Patent 8937057.
10. Kumar G.S., Kumar A., Verma A. et al. Treatment of VKC comparison between topical Cyclosporine 0.05% and Fluorometholone 0.1% in terms of efficacy and safety // Ind. J. Clin. Exp. Ophthalmol. – 2015. – Vol. 1, № 1. – R. 22-28.
11. Pucci N., Novembre E., Cianferoni A. et al. Efficacy and safety of CSA eyedrops in vernal keratoconjunctivitis // Ann. Allergy Asthma Immunol. – 2002. – Vol. 89, № 3. – P. 298-303.
12. Yanni J.M., Gamache D.A., Spellman J.M. et al. Comparative effects of topical ocular anti-allergy drugs on human conjunctival mast cells // Ann. Allergy Asthma Immunol. – 1997. – Vol. 79. – P. 541-545.
